GDUFA IV: Commitment letter outlines key changes to program
Kort samengevat
Following months of negotiations with industry, the US Food and Drug Administration (FDA) has published its proposed commitment letter for the Generic Drug User Fee Amendments (GDUFA IV) program.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Raps.
Lees het volledige bericht ↗